Deerland acquires Bifodan, expanding its global footprint
Scott Ravech will continue as CEO with global oversight of the newly combined company, but Steen Andersen, Bifodan’s CEO has been named president of Deerland Probiotics and Enyzmes International.
Photo © iStockphoto.com
Deerland Probiotics and Enzymes (Kennesaw, GA) has acquired Bifodan A/S (Hundested, Denmark), expanding its global footprint. A life science company specializing in developing, manufacturing, and distributing probiotic product solutions as private label dietary supplements, medical devices, and over the counter drugs, Bifodan is now a wholly owned subsidiary of Deerland.
Scott Ravech will continue as CEO with global oversight of the newly combined company, but Steen Andersen, Bifodan’s CEO has been named president of Deerland Probiotics and Enyzmes International. Andersen will be responsible for the Hundested site and all activities outside the Americas.
“We believe this investment will allow us to bring even greater value to our respective customers and to the enzyme and probiotic industries we serve,” said Ravech, in a press release. “Deerland and Bifodan are leaders in their respective markets. Bringing together this expertise will benefit both companies, our employees, and our customers.”
Rousselot to showcase new collagen peptide research and targeted solutions at Vitafoods Europe 2024
April 25th 2024The company will be highlighting new research that demonstrates the ability of its Peptan collagen peptide brand to support sleep quality, reduce gastrointestinal discomfort, and enhance skin health, including density, hydration, and elasticity.
